S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)

Compare Stocks

Enter up to ten stock symbols separated by a comma or space (ex. CNTG,ENZ,XGN,BIOC,OPGN).

Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ENZ
Enzo Biochem
$3.17
-0.9%
$3.30
$2.61
$4.85
$153.66M0.82163,484 shs102,982 shs
XGN
Exagen
$8.12
-3.2%
$10.55
$8.03
$24.67
$131.25M0.540,729 shs35,608 shs
BIOC
Biocept
$3.02
-0.3%
$3.70
$2.98
$8.38
$50.86M0.48198,735 shs144,685 shs
OPGN
OpGen
$0.87
-7.4%
$1.24
$0.86
$4.37
$33.90M-0.83476,853 shs764,462 shs
CNTG
Centogene
$4.27
-2.1%
$5.98
$4.10
$14.00
$84.80M-2.0512,180 shs12,726 shs

MarketRank™

CompanyOverall ScoreAnalyst's OpinionCommunity RankDividend StrengthCompany OwnershipEarnings & Valuation
ENZ
Enzo Biochem
1.21 of 5 Stars
0.04.40.01.70.0
XGN
Exagen
2.49 of 5 Stars
3.55.00.03.30.6
BIOC
Biocept
1.30 of 5 Stars
0.04.40.00.81.3
OPGN
OpGen
2.04 of 5 Stars
3.54.40.01.70.6
CNTG
Centogene
1.66 of 5 Stars
3.44.30.00.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ENZ
Enzo Biochem
0.00
N/AN/AN/A
XGN
Exagen
3.00
Buy$25.33211.99% Upside
BIOC
Biocept
3.00
BuyN/AN/A
OPGN
OpGen
3.00
Buy$3.50302.16% Upside
CNTG
Centogene
2.80
Buy$18.75339.11% Upside

Current Analyst Ratings

Latest CNTG, ENZ, XGN, BIOC, and OPGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
1/14/2022
XGN
Exagen
Cantor Fitzgerald
Reiterated RatingOverweight
1/12/2022
OPGN
OpGen
Alliance Global Partners
Lower Price Target$4.35 ➝ $3.00
12/22/2021
CNTG
Centogene
UBS Group
DowngradeBuy ➝ Neutral
12/15/2021
OPGN
OpGen
HC Wainwright
Reiterated RatingBuy$4.00
11/28/2021
CNTG
Centogene
Robert W. Baird
Reiterated RatingBuy$14.00
11/11/2021
XGN
Exagen
KeyCorp
Lower Price TargetOverweight$33.00 ➝ $30.00
10/22/2021
OPGN
OpGen
HC Wainwright
Reiterated RatingBuy
(Data available from 1/21/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ENZ
Enzo Biochem
$117.73M1.31$0.25 per share12.72$1.41 per share2.25
XGN
Exagen
$41.97M3.13N/AN/A$3.31 per share2.45
BIOC
Biocept
$27.46M1.85N/AN/A$1.77 per share1.71
OPGN
OpGen
$4.21M8.05N/AN/A$0.84 per share1.04
CNTG
Centogene
$146.64M0.58N/AN/A$3.78 per share1.13

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ENZ
Enzo Biochem
$7.88M$0.1128.82N/A4.55%11.85%6.94%3/21/2022 (Estimated)
XGN
Exagen
-$16.69M-$1.55N/AN/AN/A-48.16%-28.14%-19.50%3/15/2022 (Estimated)
BIOC
Biocept
-$17.81M$0.2213.73N/AN/A4.71%10.35%5.90%4/4/2022 (Estimated)
OPGN
OpGen
-$26.21M-$1.19N/AN/AN/A-829.32%-82.94%-45.49%3/24/2022 (Estimated)
CNTG
Centogene
-$24.49M-$1.59N/AN/AN/A-14.29%-56.32%-24.54%4/21/2022 (Estimated)

Latest CNTG, ENZ, XGN, BIOC, and OPGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
12/15/2021Q1 2022
ENZ
Enzo Biochem
N/A-$0.04-$0.04-$0.03N/A$26.52 million
11/24/20219/30/2021
CNTG
Centogene
-$0.59-$1.08-$0.49-$1.08$31.91 million$35.60 million    
11/15/20219/30/2021
BIOC
Biocept
$0.09$0.03-$0.06$0.03$16.87 million$17.47 million    
11/11/20219/30/2021
OPGN
OpGen
-$0.19-$0.16+$0.03-$0.16$1.20 million$1.24 million    
11/10/20219/30/2021
XGN
Exagen
-$0.46-$0.42+$0.04-$0.42$12.13 million$12.25 million    
(Earnings results data provided by Zacks Investment Research)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ENZ
Enzo Biochem
N/AN/AN/AN/AN/A
XGN
Exagen
N/AN/AN/AN/AN/A
BIOC
Biocept
N/AN/AN/AN/AN/A
OPGN
OpGen
N/AN/AN/AN/AN/A
CNTG
Centogene
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ENZ
Enzo Biochem
0.06
2.85
2.25
XGN
Exagen
0.30
14.62
14.62
BIOC
Biocept
0.04
4.54
4.26
OPGN
OpGen
0.19
1.55
1.48
CNTG
Centogene
N/A
1.45
1.31

Ownership

Institutional Ownership

CompanyInstitutional Ownership
ENZ
Enzo Biochem
74.57%
XGN
Exagen
62.48%
BIOC
Biocept
12.03%
OPGN
OpGen
7.52%
CNTG
Centogene
N/A

Insider Ownership

CompanyInsider Ownership
ENZ
Enzo Biochem
9.4%
XGN
Exagen
36.4%
BIOC
Biocept
1.39%
OPGN
OpGen
1.26%
CNTG
Centogene
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ENZ
Enzo Biochem
42848.47 million43.92 millionOptionable
XGN
Exagen
18216.16 million10.28 millionNot Optionable
BIOC
Biocept
10716.84 million16.61 millionOptionable
OPGN
OpGen
10238.95 million38.46 millionNot Optionable
CNTG
Centogene
60719.86 millionN/ANot Optionable

CNTG, ENZ, XGN, BIOC, and OPGN Headlines

SourceHeadline
Strategies For Global Prenatal Testing & Newborn Screening Market Players In 2022-2026 Market Forecast Period - EIN NewsStrategies For Global Prenatal Testing & Newborn Screening Market Players In 2022-2026 Market Forecast Period - EIN News
einnews.com - January 21 at 3:43 AM
Blau Syndrome Market 2022 Comprehensive Research Methodology, Regional Study by 2031 - Taiwan NewsBlau Syndrome Market 2022 Comprehensive Research Methodology, Regional Study by 2031 - Taiwan News
taiwannews.com.tw - January 21 at 3:43 AM
Global NGS Based Diagnostics Market Regional Insights, Growth Drivers, Opportunities and Trends 2021-2027 – Discovery Sports Media - Discovery Sports MediaGlobal NGS Based Diagnostics Market Regional Insights, Growth Drivers, Opportunities and Trends 2021-2027 – Discovery Sports Media - Discovery Sports Media
discoverysportsmedia.com - January 21 at 3:43 AM
Global Gene Test Service Market 2021 Revenue, Opportunity, Forecast and Value Chain 2027 – Discovery Sports Media - Discovery Sports MediaGlobal Gene Test Service Market 2021 Revenue, Opportunity, Forecast and Value Chain 2027 – Discovery Sports Media - Discovery Sports Media
discoverysportsmedia.com - January 21 at 3:43 AM
CENTOGENE teams up with Insilico Medicine to improve therapeutic targets for Niemann-Pick disease type C - News-Medical.NetCENTOGENE teams up with Insilico Medicine to improve therapeutic targets for Niemann-Pick disease type C - News-Medical.Net
news-medical.net - January 21 at 3:43 AM
Centogene Strikes Rare Disease Target Discovery Deal With Insilico Medicine - GenomeWebCentogene Strikes Rare Disease Target Discovery Deal With Insilico Medicine - GenomeWeb
genomeweb.com - January 20 at 5:42 PM
Hereditary Cancer Testing Market: Year 2021-2030 and its Detail Analysis by Focusing on Top Key Players like Ambry Genetics, ASPIRA WOMENS HEALTH, CENTOGENE NV, Color Health Inc – Discovery Sports Media - Discovery Sports MediaHereditary Cancer Testing Market: Year 2021-2030 and its Detail Analysis by Focusing on Top Key Players like Ambry Genetics, ASPIRA WOMEN'S HEALTH, CENTOGENE NV, Color Health Inc – Discovery Sports Media - Discovery Sports Media
discoverysportsmedia.com - January 20 at 12:42 PM
Centogene in Research Deal With Insilico Medicine - MarketWatchCentogene in Research Deal With Insilico Medicine - MarketWatch
marketwatch.com - January 20 at 7:41 AM
CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug DevelopmentCENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development
finance.yahoo.com - January 20 at 7:41 AM
Global Mitochondrial Disorders Treatment Market 2021 Opportunities and Key Players To 2027 – Khondrion, Ixchel Pharma, Reata Pharmaceuticals, Mitobridge – Discovery Sports Media - Discovery Sports MediaGlobal Mitochondrial Disorders Treatment Market 2021 Opportunities and Key Players To 2027 – Khondrion, Ixchel Pharma, Reata Pharmaceuticals, Mitobridge – Discovery Sports Media - Discovery Sports Media
discoverysportsmedia.com - January 19 at 6:47 PM
Global Mitochondrial Myopathy Diagnosis & Treatment Market 2021 Future Forecast – AbbVie, Centogene, GeneDx, Ixchel Pharma – Discovery Sports Media - Discovery Sports MediaGlobal Mitochondrial Myopathy Diagnosis & Treatment Market 2021 Future Forecast – AbbVie, Centogene, GeneDx, Ixchel Pharma – Discovery Sports Media - Discovery Sports Media
discoverysportsmedia.com - January 17 at 4:06 AM
Centogene (NASDAQ:CNTG) Receives Average Recommendation of "Buy" from AnalystsCentogene (NASDAQ:CNTG) Receives Average Recommendation of "Buy" from Analysts
americanbankingnews.com - January 16 at 9:04 AM
2 Trials to Test Oral BIIB122/DNL151 in Slowing Parkinsons... - Parkinsons News Today2 Trials to Test Oral BIIB122/DNL151 in Slowing Parkinson's... - Parkinson's News Today
parkinsonsnewstoday.com - January 13 at 11:27 AM
Global Non-Invasive Prenatal Testing (NIPT) Market 2020-2031: Focus on Method, Test, Platform, End-user, Application and Country - ResearchAndMarkets.com - Business WireGlobal Non-Invasive Prenatal Testing (NIPT) Market 2020-2031: Focus on Method, Test, Platform, End-user, Application and Country - ResearchAndMarkets.com - Business Wire
businesswire.com - January 13 at 1:04 AM
Arcensus has appointed Prof. Dr. Arndt Rolfs as New CEO - marketscreener.comArcensus has appointed Prof. Dr. Arndt Rolfs as New CEO - marketscreener.com
marketscreener.com - January 12 at 10:02 AM
Clinical Biomarkers Market to Witness a Pronounce Growth During 2026 - Northwest Diamond NotesClinical Biomarkers Market to Witness a Pronounce Growth During 2026 - Northwest Diamond Notes
nwdiamondnotes.com - January 10 at 1:32 PM
Denali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022 - StreetInsider.comDenali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022 - StreetInsider.com
streetinsider.com - January 10 at 1:32 PM
New Update on NGS Based Diagnostics Market 2021 Analysis by Competitive landscape, Industry Insights and Forecast to 2027 – Industrial IT - Industrial ITNew Update on NGS Based Diagnostics Market 2021 Analysis by Competitive landscape, Industry Insights and Forecast to 2027 – Industrial IT - Industrial IT
industrialit.com.au - January 10 at 1:32 PM
Europe Mitochondrial Myopathy Diagnosis & Treatment Market Size is set to Grow at a Remarkable Pace in the Coming Years – Industrial IT - Industrial ITEurope Mitochondrial Myopathy Diagnosis & Treatment Market Size is set to Grow at a Remarkable Pace in the Coming Years – Industrial IT - Industrial IT
industrialit.com.au - January 10 at 1:32 PM
Global Non-Invasive Prenatal Testing (NIPT) Market: Focus on Method, Test, Platform, End User, Application and Country Analysis - Analysis and Forecast, 2020-2031 - Yahoo FinanceGlobal Non-Invasive Prenatal Testing (NIPT) Market: Focus on Method, Test, Platform, End User, Application and Country Analysis - Analysis and Forecast, 2020-2031 - Yahoo Finance
finance.yahoo.com - January 10 at 7:49 AM
Mitochondrial Disorders Treatment Market Covid-19 Impact In-Depth Industry Analysis 2026 - Northwest Diamond NotesMitochondrial Disorders Treatment Market Covid-19 Impact In-Depth Industry Analysis 2026 - Northwest Diamond Notes
nwdiamondnotes.com - January 10 at 7:49 AM
Hereditary Cancer Testing Market 2021 Global Demand and Emerging Trends by 2030- Ambry Genetics, ASPIRA WOMENS HEALTH, CENTOGENE NV, Color Health Inc., Fulgent Genetics – Industrial IT - Industrial ITHereditary Cancer Testing Market 2021 Global Demand and Emerging Trends by 2030- Ambry Genetics, ASPIRA WOMEN'S HEALTH, CENTOGENE NV, Color Health Inc., Fulgent Genetics – Industrial IT - Industrial IT
industrialit.com.au - January 7 at 8:34 PM
New Products Posted to GenomeWeb: Phase Genomics, Centogene, Biotium - GenomeWebNew Products Posted to GenomeWeb: Phase Genomics, Centogene, Biotium - GenomeWeb
genomeweb.com - January 7 at 8:34 PM
Cancer Genomic Testing Market Report Covers Future Trends with In-depth Analysis & Research 2022-2028 | | Key Players -Myriad Genetics, Positive Bioscience, Quest Diagnostics, Centogene AG, LabCorp… – Industrial IT - Industrial ITCancer Genomic Testing Market Report Covers Future Trends with In-depth Analysis & Research 2022-2028 | | Key Players -Myriad Genetics, Positive Bioscience, Quest Diagnostics, Centogene AG, LabCorp… – Industrial IT - Industrial IT
industrialit.com.au - January 7 at 3:33 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.